Study to Evaluate the Safety and Tolerability of EP0042
Recruiting now · Phase 1/Phase 2
Conditions studied: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
In brief
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).
Key facts
- Study ID
- NCT04581512
- Run by
- Ellipses Pharma
- People needed
- 70
- Starts
- 2020-11-02
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-06-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Royal Perth Hospital — Perth, Western Australia, Australia (enrolling)
- Amsterdam UMC — Amsterdam, Netherlands (enrolling)
- Erasmus MC — Rotterdam, Netherlands (enrolling)
- The Royal Marsden — London, UK, United Kingdom (enrolling)
- University College London Hospital — London, United Kingdom (enrolling)
- The Christie Hospital — Manchester, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.